COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01193595
Recruitment Status : Completed
First Posted : September 2, 2010
Last Update Posted : December 3, 2014
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

- To determine the maximum administered dose (MAD) and the maximum tolerated dose (MTD) of ombrabulin in combination with best tolerated dose of bevacizumab based on the incidence of related Dose Limiting Toxicities (DLTs).

Secondary Objectives:

  • To assess the overall safety profile of the combination
  • To characterize the pharmacokinetic (PK) profile of both ombrabulin and bevacizumab when given in combination
  • To evaluate preliminary evidence of anti-tumor activity
  • To assess the pharmacodynamic effect using (Dynamic Contrast Enhanced Ultra-Sound) DCE-US, measuring biomarkers

Condition or disease Intervention/treatment Phase
Neoplasms, Malignant Drug: Ombrabulin (AVE8062) Drug: bevacizumab Phase 1

Detailed Description:
The duration of the study for each patient will include an up to 28-day screening phase, 21-day study treatment cycles, an end of treatment visit with a follow-up period. Each patient will participate in only one dose group and will receive AVE8062 with bevacizumab every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Non-randomized, Dose Escalation, Safety and Pharmacokinetic Phase I Study of Ombrabulin (AVE8062) in Combination With Bevacizumab Administered by Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid Tumors.
Study Start Date : September 2010
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: AVE8062/ bevacizumab
The combination of ombrabulin and bevacizumab will be administered every 3 weeks according to the following schedule: One day 1, ombrabulin will be administered as a 30 minutes intravenous (i.v) infusion. Bevacizumab will be administered as a 30-90 minutes i.v. infusion 24 hours after the end of ombrabulin infusion on day 2.
Drug: Ombrabulin (AVE8062)

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Drug: bevacizumab

Pharmaceutical form:Solution for infusion

Route of administration: Intravenous

Primary Outcome Measures :
  1. Incidence of Dose Limiting Toxicities (DLTs) that will define the MTD [ Time Frame: 3 weeks ]

Secondary Outcome Measures :
  1. Overall safety profile of the combination [ Time Frame: up to a maximum follow-up of 1 year ]
  2. Pharmacokinetic parameters of ombrabulin [ Time Frame: 6 weeks ]
  3. Pharmacokinetic parameters of bevacizumab [ Time Frame: 6 weeks ]
  4. Preliminary evidence of antitumor activity according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) [ Time Frame: up to a maximum follow-up of 1 year ]
  5. Pharmacodynamic effect (biomarkers) [ Time Frame: cycle 1 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically or cytologically proven solid malignant tumor at the first diagnosis with the exception of squamous non small cell lung cancer (NSCLC).
  • Advanced neoplastic disease (i.e. metastatic or locally unresectable advanced disease)
  • Presence of one measurable lesion at baseline in the MTD expanded cohort

Exclusion criteria:

  • ECOG (Eastern cooperativeOncology Group) performance status > 1
  • Concurrent treatment with any other anticancer therapy
  • Pericardial effusion requiring intervention (drainage)
  • History of brain metastasis, spinal cord compression or carcinomatous meningitis or new evidence of brain metastasis on screening Computed tomography (CT) or Magnetic resonance imaging (MRI) scan
  • Diagnosis of squamous Non Squamous Cell Lung Cancer (NSCLC) or with mixed cell type with predominant squamocellular histology
  • Hormone sensitive prostate cancer
  • Abdominal Radiotherapy
  • Major surgery within the last month of study enrollment or surgical wound not fully healed before study enrollment
  • High cumulative doses of anthracycline
  • Inadequate organ function
  • Inadequate hematology function or poor bone marrow reserve
  • Any of the following within 6 months prior to study enrollment: peptic ulcer disease, erosive oesophagitis or gastritis, infectious or inflammatory bowel disease and diverticulitis
  • Any history or underlying cardiac condition that may increase the risks associated with the study participation or administration of the investigational products, or that may interfere with the interpretation of the results.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01193595

Layout table for location information
Investigational Site Number 250001
Villejuif Cedex, France, 94805
Investigational Site Number 380002
Milano, Italy, 20132
Investigational Site Number 380001
Milano, Italy, 20133
United Kingdom
Investigational Site Number 826001
Sutton, United Kingdom, SM2 5PT
Sponsors and Collaborators
Layout table for investigator information
Study Director: Clinical Sciences & Operations Sanofi
Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT01193595    
Other Study ID Numbers: TCD11379
2009-017797-20 ( EudraCT Number )
First Posted: September 2, 2010    Key Record Dates
Last Update Posted: December 3, 2014
Last Verified: December 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors